AbbVie Stock at $225: Does 45% Gain Justify the Valuation?

AbbVie (NYSE:ABBV) has surged 53.59% since the start of 2024 to $224.95, placing it at the center of a sharp bull-bear debate. While the company is an immunology heavyweight with drugs Skyrizi, Rinvoq, and Humira, its balance sheet shows negative shareholders' equity of -$6.6 billion, complicating conviction at this price.

Rating Change

No official rating change has been issued by analysts, but the analysis suggests the stock at $225 may be overvalued given the financial risks. The current rating is "Hold" according to 24/7 Wall St.

Analyst Rationale

Analysts focus on two key factors:

• Strong Growth: The 53.59% gain since 2024 reflects market confidence in AbbVie's newer drugs like Skyrizi and Rinvoq.
• Financial Risk: Negative shareholders' equity of $6.6 billion raises questions about the company's ability to service debt or maintain stable dividends.

Context

The positive stock performance comes amid intense competition from similar biologics, especially after Humira's patent expiration. Other analysts see potential headwinds if new products fail to meet revenue expectations.

What We Conclude

Given current data, AbbVie stock at $225 appears a neutral choice. New investors may wait for a pullback to reduce risk, while current holders may prefer to hold for continued growth.